Table 3.

Characteristics and outcomes of patients infected with colistin-resistant Acinetobacter baumannii

Patient number	Age (years)	Sex	Comorbidity	Diagnosis	ICU	Septic shock	Prior colistin use	Regimen	Treatment duration (days)	Clinical outcome
1	58	M	DM	VAP	Yes	Yes	No	COL IMP	14	Improvement
2	81	M	DM, ESRD with HD	VAP	Yes	Yes	Yes	SUL LVX	5	Death
3	67	M	SCLC, RF	VAP	Yes	Yes	Yes	COL FOS	14	Death
4	91	F	PAD, HT, DLP, RF	Septicemia	Yes	Yes	No	COL SUL	11	Death
5	61	M	BPH, HT, RF	UTI	No	No	No	COL SUL	10	Improvement
6	90	F	HT, RF	Bacterial peritonitis	Yes	Yes	Yes	COL IMP	3	Death
7	77	M	DM, CA	Cholangitis	No	Yes	No	COL IMP	14	Death
8	81	M	HT, COPD	HAP	No	Yes	No	COL IMP	17	Improvement
9	63	F	DM, HD	Cellulitis	Yes	Yes	Yes	COL IMP	13	Death
10	82	M	HT, RF	VAP	Yes	Yes	Yes	COL MEP	12	Death
11	21	M	AKI with CVVHDF	Septicemia	Yes	Yes	No	COL MEP	4	Death
12	55	M	ALL, AKI	Septicemia	Yes	Yes	No	COL IMP	11	Death
13	80	F	HT, DM	Septicemia	No	Yes	No	COL IMP	21	Cure
14	83	M	HT, DM	Cholangitis, septicemia	No	Yes	No	COL IMP	18	Cure
15	63	F	DM	Cholangitis, septicemia	No	Yes	No	COL FOS	10	Death
16	76	M	HT, ESRD with HD	Septicemia	Yes	Yes	No	COL IMP	11	Death
17	85	F	AKI with HD	VAP with pleural effusion	Yes	Yes	No	TIG SUL	25	Death

Abbreviations: AKI, acute kidney injury; ALL, acute lymphoblastic leukemia; BPH, benign prostatic hyperplasia; CA, cancer; COL, colistin; COPD, chronic obstructive pulmonary disease; CVVHDF, continuous veno-venous hemodiafiltration; DLP, dyslipidemia; DM, diabetes mellitus; ESRD, end-stage renal disease; FOS, fosfomycin; HAP, hospital-acquired pneumonia; HD, hemodialysis; HT, hypertension; ICU, intensive care unit; IMP, imipenem; LVX, levofloxacin; MEP, meropenem; PAD, peripheral artery disease; RF, renal failure; SCLC, small cell lung cancer; SUL, sulbactam; TIG, tigecycline; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.